These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22217967)

  • 1. Total lymphocyte count as a surrogate marker to predict CD4 count in human immunodeficiency virus-infected children: a retrospective evaluation.
    Wang Y; Li Y; Wang C; Liang S; Guo J; Li Z; Zhang M; Li W
    Pediatr Infect Dis J; 2012 Jan; 31(1):61-3. PubMed ID: 22217967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total lymphocyte count: a surrogate marker for predicting CD4+ count in enrolled process for antiretroviral therapy in resource-limited settings.
    Susaengrat W; Mitchai M; Leerattanapetch N
    J Med Assoc Thai; 2008 Oct; 91(10):1514-7. PubMed ID: 18972893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation analysis on total lymphocyte count and CD4 count in HIV-infected patients: a retrospective evaluation.
    Wang Y; Liang S; Yu E; Guo J; Li Z; Wang Z; Du Y
    J Huazhong Univ Sci Technolog Med Sci; 2011 Oct; 31(5):712. PubMed ID: 22038367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings.
    Mahajan AP; Hogan JW; Snyder B; Kumarasamy N; Mehta K; Solomon S; Carpenter CC; Mayer KH; Flanigan TP
    J Acquir Immune Defic Syndr; 2004 May; 36(1):567-75. PubMed ID: 15097299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation analysis on total lymphocyte count and CD4 count of HIV-infected patients.
    Liu FR; Guo F; Ye JJ; Xiong CF; Zhou PL; Yin JG; Ye LX
    Int J Clin Pract; 2008 Jun; 62(6):955-60. PubMed ID: 17983435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total lymphocyte count is a good marker for HIV-related mortality and can be used as a tool for starting HIV treatment in a resource-limited setting.
    Oudenhoven HP; Meijerink H; Wisaksana R; Oetojo S; Indrati A; van der Ven AJ; van Asten HA; Alisjahbana B; van Crevel R
    Trop Med Int Health; 2011 Nov; 16(11):1372-9. PubMed ID: 21883724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting CD4 count using total lymphocyte count: a sustainable tool for clinical decisions during HAART use.
    Mwamburi DM; Ghosh M; Fauntleroy J; Gorbach SL; Wanke CA
    Am J Trop Med Hyg; 2005 Jul; 73(1):58-62. PubMed ID: 16014833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
    Bisson GP; Gross R; Strom JB; Rollins C; Bellamy S; Weinstein R; Friedman H; Dickinson D; Frank I; Strom BL; Gaolathe T; Ndwapi N
    AIDS; 2006 Aug; 20(12):1613-9. PubMed ID: 16868442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment.
    Florence E; Dreezen C; Schrooten W; Van Esbroeck M; Kestens L; Fransen K; De Roo A; Colebunders R
    Int J STD AIDS; 2004 Aug; 15(8):538-42. PubMed ID: 15307965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of total lymphocyte count (TLC) as an independent criterion for initiating HAART in resource-poor countries.
    Lee SS; Wong KH
    J Infect; 2005 Jan; 50(1):66-7. PubMed ID: 15603843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people.
    Stebbing J; Sawleshwarkar S; Michailidis C; Jones R; Bower M; Mandalia S; Nelson M; Gazzard B
    Postgrad Med J; 2005 Sep; 81(959):586-8. PubMed ID: 16143689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumocystis jirovecii prophylaxis discontinuation based upon total lymphocyte count in HIV-infected adults treated with antiretroviral therapy.
    Cheung C; Shuter J
    Int J STD AIDS; 2010 Jun; 21(6):406-9. PubMed ID: 20606220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of total lymphocyte count for monitoring response to antiretroviral therapy.
    Schreibman T; Friedland G
    Clin Infect Dis; 2004 Jan; 38(2):257-62. PubMed ID: 14699459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
    J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
    Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
    Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
    Dragsted UB; Mocroft A; Vella S; Viard JP; Hansen AB; Panos G; Mercey D; Machala L; Horban A; Lundgren JD;
    J Infect Dis; 2004 Jul; 190(1):148-55. PubMed ID: 15195254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.